Neurocrine Bio. (NBIX) PT Raised to $138 at Stifel; Nice Ingrezza Beat and Better TRx Commentary

August 3, 2021 5:54 PM EDT
Get Alerts NBIX Hot Sheet
Price: $94.99 -0.06%

Rating Summary:
    22 Buy, 9 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Paul Matteis raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $138.00 (from $136.00) while maintaining a Buy rating following results.

The analyst commented, "We are reiterating our Buy rating on NBIX on the back of a solid 2Q for Ingrezza: sales were $265MM, vs consensus of $257MM. We had however viewed consensus as conservative, so what was more impressive to us was NBIX commentary that NRx reached their best levels since last March, while refill rates reached pre-pandemic levels. We are updating our model for the quarter, our Target Price goes to $138 from $136."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Stifel